A large study by researchers at the American Cancer Society demonstrated that adult cancer survivors, particularly those diagnosed within five years and/or those who have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to older adults without cancer.
Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.
